Examiner: TAO, BIN

Tech Center 1600 • Art Units: 1625

This examiner grants 100% of resolved cases

Performance Statistics

100.0%

Allow Rate

+40.0% vs TC avg

Total Applications

+0.0%

Interview Lift

927

Avg Prosecution Days

Based on 1 resolved cases, 2023–2026

§101 Eligibility

15.4%

§102 Novelty

38.5%

§103 Obviousness

23.1%

§112 Clarity

App #	Title	Status	Assignee
17791571	Combination Therapy	Non-Final OA	NATIONAL UNIVERSITY OF SINGAPORE
18577071	Pharmaceutical Composition for Preventing or Treating Systemic Sclerosis	Non-Final OA	Daewoong Pharmaceutical Co., Ltd.
18481723	CRYSTALLINE FORMS OF A PARP1 INHIBITOR	Non-Final OA	XinThera, Inc.

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.